Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites

Gene

Volumn 483, Issue 1-2, 2011, Pages 29-35

  Khan, Maola M G ^a,g   Rydén, Anna Margareta ^b   Chowdhury, M Sanaullah ^c   Hasan, Md Ashraful ^d   Kazi, Julhash U ^e,f  

^a JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF CHITTAGONG   (Bangladesh)

^d Hallym University   (South Korea)

^e KN Biomedical Research Institute   (Bangladesh)

^f Opsonin Pharma Limited   (Bangladesh)

^g RIKEN   (Japan)

Author keywords

Maximum likelihood; P53; Phylogenetic analysis

Indexed keywords

AMINO ACID; PROTEIN P53;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CODON; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; HUMAN; MAMMAL; MAXIMUM LIKELIHOOD METHOD; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; CODON; EVOLUTION, MOLECULAR; GENES, P53; HUMANS; LIKELIHOOD FUNCTIONS; MAMMALS; MUTATION; NEOPLASMS; PHYLOGENY; SELECTION, GENETIC; SEQUENCE ALIGNMENT;

MAMMALIA;

EID: 79960250940     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.05.011     Document Type: Article

References (34)

1. Arrowsmith C.H. Structure and function in the p53 family. Cell Death Differ. 1999, 6:1169-1173.
2. Beckman G., et al. Is p53 polymorphism maintained by natural selection?. Hum. Hered. 1994, 44:266-270.
3. Benard J., Douc-Rasy S., Ahomadegbe J.C. TP53 family members and human cancers. Hum. Mutat. 2003, 21:182-191.
4. Beroud C., Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum. Mutat. 2003, 21:176-181.
5. Denissenko M.F., Chen J.X., Tang M.S., Pfeifer G.P. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3893-3898.
6. Fenoglio-Preiser C.M., Wang J., Stemmermann G.N., Noffsinger A. TP53 and gastric carcinoma: a review. Hum. Mutat. 2003, 21:258-270.
7. Ford M.J. Effects of natural selection on patterns of DNA sequence variation at the transferrin, somatolactin, and p53 genes within and among chinook salmon (Oncorhynchus tshawytscha) populations. Mol. Ecol. 2000, 9:843-855.
8. Gasco M., Yulug I.G., Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum. Mutat. 2003, 21:301-306.
9. Goldman N., Yang Z. A codon-based model of nucleotide substitution for protein-coding DNA sequences. Mol. Biol. Evol. 1994, 11:725-736.
10. Harms K.L., Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol. Cell. Biol. 2005, 25:2014-2030.
11. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 1996, 88:1442-1455.
12. Hofseth L.J., Hussain S.P., Harris C.C. p53: 25years after its discovery. Trends Pharmacol. Sci. 2004, 25:177-181.
13. Iacopetta B. TP53 mutation in colorectal cancer. Hum. Mutat. 2003, 21:271-276.
14. Keimling M., Wiesmuller L. DNA double-strand break repair activities in mammary epithelial cells-influence of endogenous p53 variants. Carcinogenesis 2009, 30:1260-1268.
15. Koonin E.V., Rogozin I.B., Glazko G.V. p53 gain-of-function: tumor biology and bioinformatics come together. Cell Cycle 2005, 4:686-688.
16. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15-16.
17. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature 1991, 351:453-456.
18. Li Y.Z., Lu D.Y., Tan W.Q., Wang J.X., Li P.F. p53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC. Mol. Cell. Biol. 2008, 28:564-574.
19. Nitta M., Okamura H., Aizawa S., Yamaizumi M. Heat shock induces transient p53-dependent cell cycle arrest at G1/S. Oncogene 1997, 15:561-568.
20. Pintus S.S., Fomin E.S., Ivanisenko V.A., Kolchanov N.A. Phylogenetic analysis of the family of p53. Biofizika 2006, 51:640-649.
21. Pintus S.S., Fomin E.S., Oshurkov I.S., Ivanisenko V.A. Phylogenetic analysis of the p53 and p63/p73 gene families. In Silico Biol. 2007, 7:319-332.
22. Rodin S.N., Rodin A.S. Origins and selection of p53 mutations in lung carcinogenesis. Semin. Cancer Biol. 2005, 15:103-112.
23. Soussi T., Beroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum. Mutat. 2003, 21:192-200.
24. Soussi T., Ishioka C., Claustres M., Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 2006, 6:83-90.
25. Tornaletti S., Pfeifer G.P. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 1995, 10:1493-1499.
26. Tornaletti S., Pfeifer G.P. UV light as a footprinting agent: modulation of UV-induced DNA damage by transcription factors bound at the promoters of three human genes. J. Mol. Biol. 1995, 249:714-728.
27. Toyooka S., Tsuda T., Gazdar A.F. The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat. 2003, 21:229-239.
28. Walker D.R., et al. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 1999, 18:211-218.
29. Yang Z. Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol. Biol. Evol. 1998, 15:568-573.
30. Yang Z. PAML 4: phylogenetic analysis by maximum likelihood. Mol. Biol. Evol. 2007, 24:1586-1591.
31. Yang Z., Nielsen R. Synonymous and nonsynonymous rate variation in nuclear genes of mammals. J. Mol. Evol. 1998, 46:409-418.
32. Yang Z., Nielsen R. Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages. Mol. Biol. Evol. 2002, 19:908-917.
33. Yang Z., Swanson W.J. Codon-substitution models to detect adaptive evolution that account for heterogeneous selective pressures among site classes. Mol. Biol. Evol. 2002, 19:49-57.
34. Yoshida K., Miki Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci. 2010, 19:831-835.